[HTML][HTML] Targeting mutant p53 for cancer therapy: direct and indirect strategies
J Hu, J Cao, W Topatana, S Juengpanich, S Li… - Journal of hematology & …, 2021 - Springer
TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …
Emerging combination strategies with phototherapy in cancer nanomedicine
Optical techniques using developed laser and optical devices have made a profound impact
on modern medicine, with “biomedical optics” becoming an emerging field. Sophisticated …
on modern medicine, with “biomedical optics” becoming an emerging field. Sophisticated …
A tetrahedral framework DNA‐based bioswitchable miRNA inhibitor delivery system: application to skin anti‐aging
MicroRNA (miR)‐based therapy shows strong potential; however, structural limitations pose
a challenge in fully exploiting its biomedical functionality. Tetrahedral framework DNA (tFNA) …
a challenge in fully exploiting its biomedical functionality. Tetrahedral framework DNA (tFNA) …
Polymeric delivery of therapeutic nucleic acids
R Kumar, CF Santa Chalarca, MR Bockman… - Chemical …, 2021 - ACS Publications
The advent of genome editing has transformed the therapeutic landscape for several
debilitating diseases, and the clinical outlook for gene therapeutics has never been more …
debilitating diseases, and the clinical outlook for gene therapeutics has never been more …
[HTML][HTML] The role and mechanisms of action of microRNAs in cancer drug resistance
W Si, J Shen, H Zheng, W Fan - Clinical epigenetics, 2019 - Springer
MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which
can regulate various target genes and are thus involved in the regulation of a variety of …
can regulate various target genes and are thus involved in the regulation of a variety of …
The risks of miRNA therapeutics: in a drug target perspective
S Zhang, Z Cheng, Y Wang, T Han - Drug design, development …, 2021 - Taylor & Francis
RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs,
were approved by the Food and Drug Administration in 2018 and 2019, respectively …
were approved by the Food and Drug Administration in 2018 and 2019, respectively …
Non-coding RNAs and potential therapeutic targeting in cancer
Recent advances have begun to clarify the physiological and pathological roles of non-
coding RNAs (ncRNAs) in various diseases, including cancer. Among these, microRNAs …
coding RNAs (ncRNAs) in various diseases, including cancer. Among these, microRNAs …
[HTML][HTML] Advances in the delivery of RNA therapeutics: from concept to clinical reality
The rapid expansion of the available genomic data continues to greatly impact biomedical
science and medicine. Fulfilling the clinical potential of genetic discoveries requires the …
science and medicine. Fulfilling the clinical potential of genetic discoveries requires the …
[HTML][HTML] Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
CC Jiang, LS Lin, S Long, XY Ke, K Fukunaga… - Signal transduction and …, 2022 - nature.com
Autism spectrum disorder (ASD) is a prevalent and complex neurodevelopmental disorder
which has strong genetic basis. Despite the rapidly rising incidence of autism, little is known …
which has strong genetic basis. Despite the rapidly rising incidence of autism, little is known …
[HTML][HTML] Promoting tissue regeneration by modulating the immune system
The immune system plays a central role in tissue repair and regeneration. Indeed, the
immune response to tissue injury is crucial in determining the speed and the outcome of the …
immune response to tissue injury is crucial in determining the speed and the outcome of the …